FIELD MATRIX / 04 SUBJECTS
Compare the evidence, not the aura
Four research stories placed on the same grid: what each molecule is, where it acts, and how far its evidence has progressed.
In plain English
These four molecules do not compete to do the same job. NAD+ is a cellular coenzyme involved in energy chemistry and enzyme signaling. BPC-157 is a synthetic peptide fragment studied mainly for repair in animals and cells. GHK-Cu is a natural three-amino-acid copper complex explored mostly through skin, matrix, and topical research. PT-141 is a designed cyclic peptide that activates brain melanocortin receptors and, as bremelanotide, has an approved clinical use.
The fairest comparison is therefore not “which one works best?” It is which question each body of evidence can answer. NAD+ precursor trials can show a blood biomarker response [2][5]. BPC-157 models can reveal a candidate repair pathway [11][12]. GHK-Cu studies can test topical formulation and specific skin or hair outcomes [13][15][17]. PT-141 trials can estimate clinical effects and adverse events in a defined population [20][21]. Different study stages produce different kinds of confidence. The table below keeps those stages visible.
Four paths through peptide science
| Subject | What it is | Main research focus | Strongest evidence here | Evidence boundary |
|---|---|---|---|---|
| NAD+ | Endogenous redox coenzyme; not a peptide | Cellular energy, NAD-consuming enzymes, ageing biology | Controlled human precursor studies raise blood NAD+ [2][5] | Clinical outcomes and tissue-specific effects remain inconsistent or sparse [1] |
| BPC-157 | Synthetic 15-amino-acid gastric-protein fragment | Cytoprotection, angiogenesis, tissue repair | Coherent animal and cell findings; a two-person safety pilot [8][11][12] | No rigorous large-scale human efficacy trials [9] |
| GHK-Cu | Natural tripeptide bound to copper | Matrix remodeling, topical skin delivery, hair formulations | Reviews of small topical studies and one combination hair trial [13][15][16] | Broad systemic and anti-ageing claims exceed controlled human evidence |
| PT-141 | Designed cyclic melanocortin agonist; bremelanotide | Central sexual desire and arousal pathways | Human neuroimaging, Phase 3 trials, long-term extension, regulatory label [19][20][21][22] | Approval is limited to a defined condition and population |
Mechanism: four different biological scales
NAD+ works at the scale of basic cellular chemistry. The NAD+/NADH pair transfers electrons, while sirtuins, PARPs, and CD38 consume NAD+ for signaling [4]. It is everywhere in the map rather than aimed at one receptor. That reach makes the biology important and broad claims difficult to isolate.
BPC-157 research centers on coordinated repair signals. VEGFR2 internalization, Akt, and endothelial nitric-oxide synthase form its clearest experimental pathway [11]. GHK-Cu works as both a copper carrier and a matrix-related signal, influencing fibroblast activity and broad gene-expression programs [14][16]. Both mechanisms are plausible, but much of the support lives before large human trials.
PT-141 is more receptor-specific. It activates MC4R and MC3R in central circuits and changes brain processing associated with desire [19]. That specificity made a narrower development program possible. The contrast is instructive: a broad mechanism can generate many hypotheses, while a receptor-targeted analogue may produce a tighter clinical question.
Evidence maturity: do not flatten the ladder
Evidence maturity is not a verdict on whether a molecule is interesting. It describes which uncertainties have been reduced. BPC-157's two-person pilot can only offer a small initial safety observation [8]. The current review still finds only three pilot studies and no rigorous large trials [9]. GHK-Cu has more human topical context, but the hair result comes from a combination product and the skin literature faces delivery limitations [13][15]. NAD+ has controlled human precursor trials, yet the newest synthesis still calls clinical efficacy limited [1].
PT-141 sits furthest along this particular ladder. Its program includes controlled mechanistic research, two Phase 3 trials, a year-long extension, and an approved label [19][20][21][22]. Even there, statistically significant average changes do not imply universal response, and nausea remains common [21]. Research maturity replaces vague possibility with defined benefit, population, and risk. It does not remove caveats.
A practical reading order
For cellular fundamentals, begin with NAD+ and watch how a reliable biomarker effect can remain separate from a clinical outcome. For the distinction between animal repair findings and human proof, read BPC-157. For formulation, chemical form, and the limits of combination studies, continue to GHK-Cu. Finish with PT-141 to see how a designed analogue moves through clinical development and acquires a narrow regulatory identity.
Across every page, the same method applies: name the molecule precisely, keep the model attached to the result, distinguish a pathway marker from a benefit, and read adverse findings beside desired ones. The shared references make that trail inspectable. Veda's purpose is orientation, and good orientation preserves distance as carefully as direction.